Trial reportEuropean heart journal2009
The effects of aetiology on outcome in patients treated with cardiac resynchronization therapy in the CARE-HF trial.
Trial report in European heart journal, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
49 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- The effect of cardiac resynchronization without a defibrillator on morbidity and mortality: an individual patient data meta-analysis of COMPANION and CARE-HF.European journal of heart failure · 2022Pooled it
- Pooled it
- Impact of etiology on the outcomes in heart failure patients treated with cardiac resynchronization therapy: a meta-analysis.PloS one · 2014Pooled it
- Current Status of Implantable Cardioverter-Defibrillators (ICDs)/Cardiac Resynchronization Therapy With Defibrillators (CRT-Ds) for Primary Prevention of Sudden Cardiac Death.Journal of arrhythmia · 2026Review
- Refining Patient Selection Criteria for LV-Only Fusion Pacing in Cardiac Resynchronization Therapy: A Systematic Review.Journal of clinical medicine · 2025Review
- Long-term outcomes of cardiac resynchronization therapy and implantable cardioverter defibrillators in elderly patients with heart failure.BMC cardiovascular disorders · 2025Article
- Improved outcomes of cardiac resynchronization therapy with a defibrillator in systolic heart failure: Analysis of the Japan cardiac device treatment registry database.Journal of arrhythmia · 2024Article
- What determines who gets cardiac resynchronization therapy in Europe? A comparison between ESC-HF-LT registry, SwedeHF registry, and ESC-CRT Survey II.European heart journal. Quality of care & clinical outcomes · 2023Article
- Cardiac resynchronization therapy with a defibrillator in non-ischemic and ischemic patients for primary and secondary prevention of sudden cardiac death: Analysis of the Japan cardiac device treatment registry database.Journal of arrhythmia · 2023Article
- The Value of Left Ventricular Mechanical Dyssynchrony and Scar Burden in the Combined Assessment of Factors Associated with Cardiac Resynchronization Therapy Response in Patients with CRT-D.Journal of clinical medicine · 2023Article
- Identifying CRT responders: Moving from electrical to mechanical dyssynchrony.Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2022Article
- Utilization and Efficacy of Cardiac Resynchronization Therapy in Patients With Chronic Heart Failure - A Report From the CHART-2 Study.Circulation reports · 2022Article
- Contemporary ICD Use in Patients with Heart Failure.Cardiology and therapy · 2021Review
- Aetiology of Heart Failure, Rather than Sex, Determines Reverse LV Remodelling Response to CRT.Journal of clinical medicine · 2021Article
- Cardiac Resynchronization Therapy in Non-Ischemic Cardiomyopathy: Role of Multimodality Imaging.Diagnostics (Basel, Switzerland) · 2021Review
- Trends in the use of implantable cardioverter-defibrillator and cardiac resynchronization therapy device in advancing age: Analysis of the Japan cardiac device treatment registry database.Journal of arrhythmia · 2020Article
- Acute correction of electromechanical dyssynchrony and response to cardiac resynchronization therapy.ESC heart failure · 2020Article
- Association between heart failure aetiology and magnitude of echocardiographic remodelling and outcome of cardiac resynchronization therapy.ESC heart failure · 2020Article
- Prognostication of Poor Survival After Cardiac Resynchronization Therapy.Medicina (Kaunas, Lithuania) · 2020Article
- Physiologic expansion of human heart-derived cells enhances therapeutic repair of injured myocardium.Stem cell research & therapy · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsCardiac dyssynchrony is common in patients with heart failure, whether or not they have ischaemic heart disease (IHD). The effect of the underlying cause of cardiac dysfunction on the response to cardiac resynchronization therapy (CRT) is unknown. This issue was addressed using data from the CARE-HF trial. METHODS AND
resultsPatients (n = 813) were grouped by heart failure aetiology (IHD n = 339 vs. non-IHD n = 473), and the primary composite (all-cause mortality or unplanned hospitalization for a major cardiovascular event) and principal secondary (all-cause mortality) endpoints analysed. Heart failure severity and the degree of dyssynchrony were compared between the groups by analysing baseline clinical and echocardiographic variables. Patients with IHD were more likely to be in NYHA class IV (7.5 vs. 4.0%; P = 0.03) and to have higher NT-proBNP levels (2182 vs. 1725 pg/L), indicating more advanced heart failure. The degree of dyssynchrony was more pronounced in patients without IHD (assessed using mean QRS duration, interventricular mechanical delay, and aorta-pulmonary pre-ejection time). Left ventricular ejection fraction and left ventricular end-systolic volume improved to a lesser extent in the IHD group (4.53 vs. 8.50% and -35.68 vs. -58.52 cm(3)). Despite these differences, CRT improved all-cause mortality, NYHA class, and hospitalization rates to a similar extent in patients with or without IHD.
conclusionThe benefits of CRT in patients with or without IHD were similar in relative terms in the CARE-HF study but as patients with IHD had a worse prognosis, the benefit in absolute terms may be greater.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.